Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

V Mateos

Showing results (131-140 of 175) with videos related to

Pageof 18
Sort By:
Bone Marrow Transplantation|September 26, 2019
Efficacy of bortezomib to intensify the conditioning regimen and the graft-versus-host disease prophylaxis for high-risk myeloma patients undergoing transplantationT Caballero-Velázquez, C Calderón-Cabrera, L López-Corral, et al.
Leukemia|February 6, 2014
Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myelomaM A Dimopoulos, X Leleu, A Palumbo, et al.
Leukemia|January 9, 2015
The predominant myeloma clone at diagnosis, CDR3 defined, is constantly detectable across all stages of disease evolutionN Puig, I Conde, C Jiménez, et al.
The New England Journal of Medicine|August 25, 2016
Daratumumab, Bortezomib, and Dexamethasone for Multiple MyelomaAntonio Palumbo, Asher Chanan-Khan, Katja Weisel, et al.
Leukemia|May 3, 2016
Bence Jones proteinuria in smoldering multiple myeloma as a predictor marker of progression to symptomatic multiple myelomaV González-Calle, J Dávila, F Escalante, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 31, 2006
Nonmyeloablative stem cell transplantation is an effective therapy for refractory or relapsed hodgkin lymphoma: results of a spanish prospective cooperative protocolIván Alvarez, Anna Sureda, Maria D Caballero, et al.
Experimental Hematology|June 28, 2003
Positive selection for CD34+ reduces the incidence and severity of veno-occlusive disease of the liver after HLA-identical sibling allogeneic peripheral blood stem cell transplantationFederico Moscardó, Alvaro Urbano-Ispizua, Guillermo F Sanz, et al.
Leukemia|May 9, 2012
SNP-based mapping arrays reveal high genomic complexity in monoclonal gammopathies, from MGUS to myeloma statusL López-Corral, M E Sarasquete, S Beà, et al.
Leukemia|August 9, 2014
In vivo murine model of acquired resistance in myeloma reveals differential mechanisms for lenalidomide and pomalidomide in combination with dexamethasoneE M Ocio, D Fernández-Lázaro, L San-Segundo, et al.
Haematologica|June 13, 2015
Zoledronic acid as compared with observation in multiple myeloma patients at biochemical relapse: results of the randomized AZABACHE Spanish trialRamón García-Sanz, Albert Oriol, María J Moreno, et al.
Pageof 18

Showing results (131-140 of 175) with videos related to

Sort By:
Pageof 18
Bone Marrow Transplantation|September 26, 2019
Efficacy of bortezomib to intensify the conditioning regimen and the graft-versus-host disease prophylaxis for high-risk myeloma patients undergoing transplantationT Caballero-Velázquez, C Calderón-Cabrera, L López-Corral, et al.
Leukemia|February 6, 2014
Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myelomaM A Dimopoulos, X Leleu, A Palumbo, et al.
Leukemia|January 9, 2015
The predominant myeloma clone at diagnosis, CDR3 defined, is constantly detectable across all stages of disease evolutionN Puig, I Conde, C Jiménez, et al.
The New England Journal of Medicine|August 25, 2016
Daratumumab, Bortezomib, and Dexamethasone for Multiple MyelomaAntonio Palumbo, Asher Chanan-Khan, Katja Weisel, et al.
Leukemia|May 3, 2016
Bence Jones proteinuria in smoldering multiple myeloma as a predictor marker of progression to symptomatic multiple myelomaV González-Calle, J Dávila, F Escalante, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 31, 2006
Nonmyeloablative stem cell transplantation is an effective therapy for refractory or relapsed hodgkin lymphoma: results of a spanish prospective cooperative protocolIván Alvarez, Anna Sureda, Maria D Caballero, et al.
Experimental Hematology|June 28, 2003
Positive selection for CD34+ reduces the incidence and severity of veno-occlusive disease of the liver after HLA-identical sibling allogeneic peripheral blood stem cell transplantationFederico Moscardó, Alvaro Urbano-Ispizua, Guillermo F Sanz, et al.
Leukemia|May 9, 2012
SNP-based mapping arrays reveal high genomic complexity in monoclonal gammopathies, from MGUS to myeloma statusL López-Corral, M E Sarasquete, S Beà, et al.
Leukemia|August 9, 2014
In vivo murine model of acquired resistance in myeloma reveals differential mechanisms for lenalidomide and pomalidomide in combination with dexamethasoneE M Ocio, D Fernández-Lázaro, L San-Segundo, et al.
Haematologica|June 13, 2015
Zoledronic acid as compared with observation in multiple myeloma patients at biochemical relapse: results of the randomized AZABACHE Spanish trialRamón García-Sanz, Albert Oriol, María J Moreno, et al.
Pageof 18